PsyBio Therapeutics Corp.
PSYBF · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 6/30/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | 0.03 | 0.00 | 0.00 |
| FCF Yield | -116.44% | -40.60% | -9.07% | 0.00% |
| EV / EBITDA | -0.68 | -1.77 | 0.00 | -1.04 |
| Quality | ||||
| ROIC | 328.61% | -344.29% | 873.37% | -30.45% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.70 | 0.63 | 0.13 | 1.49 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 50.52% | -704.16% | -3,479.17% | -73.44% |
| Safety | ||||
| Net Debt / EBITDA | -0.03 | 0.01 | 0.00 | -1.04 |
| Interest Coverage | -206.05 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -6,621.06 | -102.91 | -99.55 | 0.00 |